Taiwan Liposome (TLC) Stock Price, News & Analysis

Company Overview

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.

Key Stats

• Today's Range: $7.00 to $7.09
• 50-Day Range: $6.76 to $7.63
• 52-Week Range: $4.07 to $7.70
• Volume: 12,421 shs
• Average Volume: 133,095 shs
• Market Capitalization: $294.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TLC Stock Analysis - Frequently Asked Questions

How were Taiwan Liposome's earnings last quarter?

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) released its earnings results on Wednesday, October, 28th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $2.28 million for the quarter, compared to analysts' expectations of $0.38 million. Taiwan Liposome had a negative trailing twelve-month return on equity of 120.45% and a negative net margin of 299.27%.

When did Taiwan Liposome IPO?

Taiwan Liposome (TLC) raised $29 million in an initial public offering on the week of November 19th 2018. The company issued 5,000,000 shares at a price of $5.80 per share. Cantor acted as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

What other stocks do shareholders of Taiwan Liposome own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Taiwan Liposome investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Trevena (TRVN), Bionano Genomics (BNGO), Pfizer (PFE), Wells Fargo & Company (WFC) and Aadi Bioscience (AADI).

Company Calendar

• Last Earnings: 10/28/2020
• Today: 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TLC
• CIK: 1722890
• Web: www.tlcbio.com
• Phone: 886226557377
• Fax: N/A
• Employees: 2,020
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,020,000.00
• Net Margins: -299.27%
• Pretax Margin: -306.10%
• Return on Equity: -120.45%
• Return on Assets: -55.11%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 3.01
• Quick Ratio: 3.01

Sales & Book Value

• Annual Sales: $3.63 million
• Price / Sales: 81.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.83 per share
• Price / Book: 8.43

Miscellaneous

• Outstanding Shares: 42,077,000
• Free Float: N/A
• Market Cap: $294.54 million
• Optionable: Not Optionable
• Beta: 0.99